pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Aug 3·1 min read
save

BioNTech appoints Sobi's Guido Oelkers as new CEO, to start by Feb 1 2027

Aug 3, 2026·read at Endpoints ↗Neutral

BioNTech announced that Guido Oelkers, currently a leader at Swedish biotech company Sobi, will become its next chief executive officer.

Oelkers is expected to take over the role no later than February 1, 2027.

Sobi said it will begin looking for a replacement for Oelkers following his departure.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “BioNTech names Sobi's Guido Oelkers as incoming CEO”

read at Endpoints ↗
80 words · retrieved Aug 3
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoElectra's $350M IPO will help it become a commercial biotechEndpoints
  • 6h agoBristol Myers scraps $100M Orum-partnered cancer drugEndpoints
  • 7h agoFDA approves Ultragenyx's gene therapy for Sanfilippo syndrome type AEndpoints
  • 7h agoInternal CMS email confirms Globe and Guard exemption planEndpoints
  • 7h agoFDA grapples with China biotech's rise across the agencyEndpoints